GlobalData on MSN15h
Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEFThe trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.
In this Science segment, we examine the European Medicines Agency's recent decision to recommend granting marketing ...
GlobalData on MSN7h
CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLCThe European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...
The EMA recommended that NUZ-001, formerly monepantel, be granted orphan medicinal product designation to treat ALS in Europe ...
The European Centre for Disease Prevention and Control (ECDC) said consumption of antibiotics in the EU had increased by one ...
Vir Biotechnology (VIR) “announced that the European Medicines Agency Committee for Orphan Medicinal Products, has issued a positive opinion on ...
ImmunityBio (IBRX) announced new data from its ongoing QUILT 3.032 study. As of November, 100 patients with Bacillus Calmette-Guerin, or ...
The global consumption of antibiotics in Portugal increased by 2% between 2019-2023, double the average increase of 1% in ...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on the results from the LAURA phase III trial, which were published in The ...
It also has a marketing application to the European Medicines Agency, with a decision expected in 2025. BridgeBio has granted ...
Bavarian Nordic, with a diverse vaccine portfolio and $340 million in contracts for 2025, offers growth potential for ...
The upcoming clinical trial conferences will host talks on supply chain resilience, AI’s growing role and forging industry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback